Your session is about to expire
← Back to Search
Bevacizumab for Glioblastoma
Study Summary
This trial is testing if repeated doses of the cancer drug Bevacizumab, delivered directly to the brain through the artery, is safe and effective in treating newly diagnosed patients with the most aggressive type of brain tumor, glioblastoma multiforme.
- Glioblastoma
- Brain Tumor
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 45 Patients • NCT02036424Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been treated with Bevacizumab before.
- Group 1: SIACI of Bevacizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Bevacizumab a new experimental drug?
"Bevacizumab is being studied in 375 active clinical trials, with 99 of those trials in Phase 3. Many of the studies for Bevacizumab are located in Taibei, Taiwan, but there are 18908 locations operating studies for Bevacizumab globally."
How many test subjects are a part of this trial?
"No, this study has completed recruitment as of the most recent update on June 20th, 2022. This trial was posted February 1st, 2013 and was last updated 534 other clinical trials for glioblastoma and 375 studies involving Bevacizumab are still recruiting patients."
For what sorts of ailments is Bevacizumab most commonly prescribed?
"Bevacizumab is used to treat various cancers, including ovarian cancer and nonsquamous non-small cell lung cancer."
Are we still enrolling people for this experiment?
"The clinicaltrials.gov website indicates that this study is no longer recruiting patients. Although the last update was on 6/20/2022, the trial originally posted on 2/1/2013. There are 909 other trials which are still looking for participants."
Share this study with friends
Copy Link
Messenger